^
    1d
    Targeting Estrogen Pathways in Breast Cancer: A Review of Current Therapies and Emerging Strategies. (PubMed, Cell Biochem Funct)
    We explore current treatment strategies-including well-known drugs such as Tamoxifen and Fulvestrant, as well as aromatase inhibitors-and explain how these therapies work and why resistance sometimes develops. This article also looks at emerging approaches, like oral estrogen receptor degraders (SERDs), combination therapies, and precision medicine techniques that tailor treatment based on each patient's unique genetic profile. Altogether, these developments represent a major step forward in our understanding and treatment of ER+ breast cancer.
    Review • Journal
    |
    ER (Estrogen receptor) • CDK4 (Cyclin-dependent kinase 4)
    |
    ER positive
    |
    tamoxifen • fulvestrant
    3d
    A Case of Hormone Receptor-Positive, HER2-Negative Metastatic Recurrent Breast Cancer Successfully Treated with Capivasertib and Fulvestrant in Late-Line Therapy (PubMed, Gan To Kagaku Ryoho)
    In the CAPItello-291 trial, capivasertib and fulvestrant demonstrated efficacy in patients with up to two prior lines endocrine therapy, but its use in late-line settings has not yet been reported. In this article, we report a case of a woman with metastatic recurrent breast cancer who was treated with capivasertib and fulvestrant was used as the late-line treatment, resulting in a progression-free survival of 8 months.
    Journal
    |
    HER-2 (Human epidermal growth factor receptor 2) • PIK3CA (Phosphatidylinositol-4,5-bisphosphate 3-kinase catalytic subunit alpha) • PTEN (Phosphatase and tensin homolog)
    |
    HR positive • HER-2 negative • PIK3CA mutation • PTEN mutation • HR positive + HER-2 negative
    |
    fulvestrant • Truqap (capivasertib)
    4d
    PREcoopERA: A Window-of-Opportunity Trial of Giredestrant +/- Triptorelin vs. Anastrozole + Triptorelin in Premenopausal Patients With ER-positive/HER2-negative Early Breast Cancer (clinicaltrials.gov)
    P2, N=231, Completed, ETOP IBCSG Partners Foundation | Recruiting --> Completed | Trial completion date: Jun 2026 --> Sep 2025 | Trial primary completion date: Jun 2026 --> Sep 2025
    Trial completion • Trial completion date • Trial primary completion date
    |
    HER-2 (Human epidermal growth factor receptor 2) • ER (Estrogen receptor)
    |
    ER positive • HER-2 negative
    |
    anastrozole • triptorelin • giredestrant (RG6171)
    4d
    A Phase III Trial Comparing HRS-8080 With Standard Endocrine Therapy in Postmenopausal Women With High-Risk Early Breast Cancer (clinicaltrials.gov)
    P3, N=4800, Not yet recruiting, Shandong Suncadia Medicine Co., Ltd.
    New P3 trial
    |
    tamoxifen • letrozole
    4d
    Comparative efficacy and safety of novel oral selective estrogen receptor degraders in ER+/HER2- advanced breast cancer: An updated systematic review and meta-analysis of randomized controlled trials. (PubMed, Cancer Treat Rev)
    Novel oral SERDs may represent a paradigm shift in managing PD after 1 L therapy, showing potential to improve PFS in selected patients.
    Retrospective data • Review • Journal
    |
    HER-2 (Human epidermal growth factor receptor 2) • ER (Estrogen receptor)
    |
    HER-2 negative • ESR1 mutation
    |
    fulvestrant
    5d
    PreEMBER: A Study of Imlunestrant (LY3484356) in Premenopausal Women With Estrogen Receptor-Positive (ER+) Human Epidermal Growth Factor Receptor 2 Negative (HER2-) Early Breast Cancer (clinicaltrials.gov)
    P2, N=600, Not yet recruiting, Eli Lilly and Company | Trial completion date: Jan 2029 --> Dec 2029
    Trial completion date
    |
    HER-2 (Human epidermal growth factor receptor 2) • ER (Estrogen receptor)
    |
    ER positive • HER-2 negative
    |
    tamoxifen • Inluriyo (imlunestrant) • goserelin acetate
    6d
    A Trial of Itraconazole Effect on HRS-8080 Pharmacokinetics in Healthy Participants (clinicaltrials.gov)
    P1, N=16, Completed, Shandong Suncadia Medicine Co., Ltd. | Active, not recruiting --> Completed
    Trial completion
    |
    itraconazole
    7d
    A Study to Evaluate the Safety, Pharmacokinetics, and Activity of GDC-0587 as a Monotherapy and in Combination With Giredestrant in Participants With Locally Advanced or Metastatic Estrogen Receptor-Positive and Human Epidermal Growth Factor Receptor 2-Negative (ER+/HER2-) Breast Cancer (clinicaltrials.gov)
    P1, N=136, Recruiting, Genentech, Inc. | Not yet recruiting --> Recruiting
    Enrollment open • First-in-human
    |
    HER-2 (Human epidermal growth factor receptor 2)
    |
    HER-2 negative
    |
    giredestrant (RG6171) • omeprazole
    8d
    Cadmium interferes with the antiproliferative effect of fulvestrant in endocrine therapy-resistant estrogen receptor α-positive breast cancer cells. (PubMed, Toxicol Lett)
    Western blotting showed that Cd pre/post-treatment did not affect FUL-induced ERα degradation. Hence, Cd could suppress the antiproliferative effect of FUL in LTED cells.
    Journal
    |
    ER (Estrogen receptor)
    |
    ER positive
    |
    fulvestrant
    11d
    Clinical Study of HRS-8080 in Combination With Dalpiciclib Isethionate Tablets in Patients With Unresectable or Metastatic Breast Cancer (clinicaltrials.gov)
    P1/2, N=146, Recruiting, Shandong Suncadia Medicine Co., Ltd. | Trial completion date: Dec 2025 --> Jun 2026 | Trial primary completion date: Oct 2025 --> Jun 2026
    Trial completion date • Trial primary completion date
    |
    AiRuiKang (dalpiciclib)
    11d
    Molecular Simulation, Pharmacophore Mapping, and 3D QSAR Modeling on Chromene-Based SERDs. (PubMed, Anticancer Agents Med Chem)
    Based on the results of pharmacophore mapping, docking, molecular simulation, and 3D QSAR studies, we have designed a new set of chromene scaffold-based derivatives as potent SERDs along with their predicted activity.
    Journal
    |
    ER (Estrogen receptor)
    |
    ER positive
    |
    fulvestrant
    12d
    Integrative In-silico, Network Pharmacology, Pharmacogenomics and In-vitro Evaluation of Fulvestrant-Loaded Zinc Oxide Nanoparticles Targeting HER2 Positive Breast Cancer. (PubMed, Pharm Res)
    This study highlights the Fulvestrant-zinc oxide nanoparticles as a promising therapeutic intervention for HER2-positive breast cancer. By undergoing computational approaches, Network analysis and pharmacogenomics.
    Preclinical • Journal
    |
    HER-2 (Human epidermal growth factor receptor 2) • PGR (Progesterone receptor)
    |
    HER-2 positive • HER-2 overexpression • HER-2 positive + HER-2 overexpression
    |
    fulvestrant